key: cord-1005846-0rlio2kw
authors: Davis, Pamela B.; Wang, QuanQiu; Xu, Rong
title: Reply to “Post‐COVID 19 neurological syndrome: A new risk factor that modifies the prognosis of patients with dementia”
date: 2022-01-03
journal: Alzheimers Dement
DOI: 10.1002/alz.12460
sha: 9d766898091db19e0de06be0d06fe3ebd5ca2d1d
doc_id: 1005846
cord_uid: 0rlio2kw

nan

gant living, among others. 1 We find the mechanism for this increased risk suggested by Dr. Lozada et al. entirely plausible. However, our study, by itself, identifies associations and cannot be used to infer causation.

We do, however, have evidence that supports the concept that inflammation is important in the pathogenesis of Alzheimer's disease (AD). Tumor necrosis factor (TNF) is a major component of the hyperinflammatory response in COVID-19. 2 Anti-inflammatory therapy with TNF antagonists was shown to delay or prevent AD in populations treated for systemic inflammatory disorders including rheumatoid arthritis. 3 We agree that long-term follow-up is essential. Indeed, in our largescale population study using informatics analytics, we intend to follow up the long-term impact of COVID-19 on populations diagnosed with dementia. 

COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US

An inflammatory cytokine signature predicts COVID-19 severity and survival

Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis

Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease?